Fenwick Represents Achieve Life Sciences in $45 Million Public Offering

Fenwick represented Achieve Life Sciences, Inc. (Nasdaq: ACHV), a late-stage specialty pharmaceutical company focused on the global development and commercialization of cytisinicline as a treatment of nicotine dependence for smoking cessation, in its underwritten public offering of 15,000,000 shares of its common stock and accompanying common warrants to purchase up to 16,766,666 shares of common stock at a public offering price of $3.00 per share and warrant. The gross proceeds from the offering, before deducting underwriting discounts and commissions and other offering expenses, were $45.0 million.

Achieve intends to use the proceeds from the offering to fund continued advancement of cytisinicline through potential U.S. Food and Drug Administration marketing approval of cytisinicline and for working capital and general corporate purposes. More information can be obtained from Achieve’s announcement.

The Fenwick transaction team included corporate partners Alan Smith, Amanda Rose and Chelsea Anderson and associates Arielle Trapp, Leeza Soulina, Warren Pugash, Ross Willmot and Jack Zukin.